Inspection Record

Pentec Health — FDA 483 Findings

US FDAInspected 2018-11-05Published 2024-01-17 5 findingsEquipment and facilityDocumentation and recordsProcess validationQuality unit oversightAseptic processing and sterility assurance

Inspectors Lisa B Orr · Christina K TheodorouThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

2Documentation and records

Batch production and control records do not include complete information relating to the production and control of each batch.

3Process validation

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

4Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing.

5Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Pentec Health company profile — full history US FDA documents, 2024 Go to Findings search